MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Incyte Company Profile (NASDAQ:INCY)

Consensus Ratings for Incyte (NASDAQ:INCY) (?)
Ratings Breakdown: 1 Hold Rating(s), 17 Buy Rating(s)
Consensus Rating:Buy (Score: 2.94)
Consensus Price Target: $107.88 (37.01% upside)

Analysts' Ratings History for Incyte (NASDAQ:INCY)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016Goldman SachsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016JMP SecuritiesReiterated RatingOutperform$100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016BMO Capital MarketsReiterated RatingBuy$91.00 -> $97.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Morgan StanleyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Jefferies GroupReiterated RatingBuy$88.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/18/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016ArgusBoost Price TargetBuy$92.00 -> $135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2016BarclaysBoost Price TargetOverweight$25.00 -> $85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Piper JaffrayBoost Price TargetOverweight$65.00 -> $125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/31/2016Bank of AmericaReiterated RatingBuy$145.00 -> $87.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016Credit SuisseInitiated CoverageOutperform$110.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/5/2016Raymond JamesInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2015UBS AGReiterated RatingBuy$130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2015NomuraBoost Price TargetBuy$126.00 -> $146.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2015SunTrustBoost Price TargetBuy$93.00 -> $120.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Incyte (NASDAQ:INCY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.11)($0.05)$153.27 million$162.98 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q414($0.09)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q3($0.06)$0.33$149.92 million$198.15 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214$0.05($0.22)$140.72 million$99.58 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114($0.17)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.02)$0.03ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2011$0.19$0.26ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Incyte (NASDAQ:INCY)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.02$0.34$0.14
Q2 20163($0.06)$0.03($0.01)
Q3 20164($0.21)($0.01)($0.09)
Q4 20164($0.19)($0.07)($0.12)
(Data provided by Zacks Investment Research)
Dividend History for Incyte (NASDAQ:INCY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Incyte (NASDAQ:INCY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Incyte (NASDAQ:INCY)
DateHeadline
06/29/16 04:35 PMArtal Group Sa Increased Incyte Corp (NASDAQ:INCY) by $39.60 Million as Shares Declined - Engelwood Daily
06/28/16 04:33 PMNew report examines the non-hodgkin lymphoma pipeline landscape and therapeutics under development market review 2016
06/26/16 09:25 AMLLS Announces 2016 Man & Woman of the Year
06/26/16 09:25 AMIncyte has designs on new, perks-laden HQ
06/26/16 09:25 AMIs Jakafi A Breakthrough For Incyte In Blood Cancers?
06/25/16 08:27 AMIncyte Gains on Jakafi's Breakthrough Status for Acute GVHD - Yahoo News
06/24/16 04:39 PMBiotech Labs Birth New Drugs—and New Fortunes - Wall Street Journal
06/24/16 07:16 AMBetter Buy: Agenus Inc. vs. bluebird bio - Motley Fool
06/23/16 04:59 PMIncyte has designs on new, perks-laden HQ - Philadelphia Business Journal (blog)
06/23/16 04:59 PMEye Catching Stocks: Hecla Mining Co. (NYSE:HL), Incyte Corporation (NASDAQ:INCY), Netflix, Inc. (NASDAQ:NFLX ... - KC Register
06/23/16 09:59 AMIncyte Reports Epacadostat Combination Study Initiation -
06/23/16 08:37 AMIncyte Gets FDA Approval For Breakthrough Therapy Status For Its Ruxolitinib - Incyte Corporation (NASDAQ: INCY) revealed Thursday that the Food and Drug Administration has granted Breakthrough Therapy Status for its ruxolitinib for the treatment of patients affected by acute graft-versus-host disease (GVHD). According to the company, there are no approved treatments for patients with acute GVHD currently. Incyte's Chief Medical Officer, Steven Stein, reacted, "Receiving Breakthrough Therapy Designation from the FDA recognizes the severe nature of acute GVHD, the clear unmet medical need of these patients, and the ...Full story available on Benzinga.com
06/23/16 07:33 AMThe Market Is Ignoring The Potential Of Scynexis' SCY-098 In Invasive Fungal Infections - Seeking Alpha
06/23/16 07:33 AMAgenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in ... - Business Wire (press release)
06/23/16 07:33 AMIncyte Announces First Patient Treated in ECHO-301 Phase 3 Study - Business Wire (press release)
06/23/16 06:49 AMFDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD) - [at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 23, 2016-- Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ruxolitinib ...
06/22/16 04:45 PMUse of baricitinib for RA linked with significantly improved patient-reported outcomes
06/22/16 04:45 PMIncyte : Phase I/II trial of INCAGN1876 in solid tumours starts
06/22/16 03:49 PMIncyte Announces First Patient Treated in ECHO-301 Phase 3 Study - [at noodls] - http://www.businesswire.com/news/home/20160622006234/en/ 'We are very pleased to treat the first patient in the ECHO-301 study and advance the Phase 3 program evaluating epacadostat in combination with ...
06/22/16 09:19 AMAGENUS INC : Other Events, Financial Statements and Exhibits (form 8-K)
06/22/16 09:19 AMAgenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
06/22/16 09:19 AMCommit To Buy Incyte Corporation At $45, Earn 11.6% Using Options
06/21/16 04:21 PMDelaware Achievers, June 26 - The News Journal
06/21/16 10:29 AMIncyte Corp. – Value Analysis (NASDAQ:INCY) : June 21, 2016 -
06/21/16 09:11 AMOpinion: Biotech stocks are in for more election trouble on drug pricing - MarketWatch
06/20/16 07:31 AMIncyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : June 20, 2016 -
06/16/16 08:54 AMFMI: Kinase Inhibitors For Cancer Treatment Market Value Share, Supply Demand 2016-2026
06/15/16 09:16 AMEndometrial Cancer 2016 Pipeline Market Research
06/14/16 09:25 AMShould Pfizer Buy This Beaten-Down Immuno-Oncology Company? - Motley Fool
06/13/16 07:23 AMIncyte Corporation (NASDAQ:INCY) at $80.41: How much higher it can go
06/13/16 07:15 AMAnalysts Very Positive on 3 Top Stocks Following Jefferies Healthcare Conference -
06/12/16 07:21 AMJakafi superior to best available therapy in mid-stage polycythemia vera study
06/10/16 08:15 AMIncyte's Jakafi Positive in Phase III for Polycythemia Study -
06/09/16 03:42 PM3 Reasons Ariad Pharmaceuticals Inc. Stock Rose 23.3% in May -
06/09/16 10:06 AMA Look at the Performance of Incyte’s Jakafi -
06/09/16 07:20 AMEli Lilly & Co. (LLY), Incyte (INCY) Report Baricitinib Superiority to Placebo in Inhibiting RA-Related Joint Damage - StreetInsider.com
06/07/16 08:45 AMIncyte Reports Five-Year Data from Phase III Study on Jakafi -
06/06/16 08:13 AMMerck & Co., Inc. (NYSE:MRK) & Ariad Pharmaceuticals, (NASDAQ:ARIA) Trending healthcare Stocks - Wall Street 24
06/06/16 08:13 AMCompany Update (NASDAQ:INCY): Incyte Corporation Announces Five-year Results from Phase 3 Study of Jakafi® - Smarter Analyst
06/06/16 06:36 AM7:36 am Incyte announces five-year data from the phase 3 Comfort-I study evaluating the long-term safety & efficacy of Jakafi in patients with intermediate-2 or high-risk myelofibrosis -
06/06/16 06:35 AMFive-year Results from Phase 3 Study of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis (MF) - [Business Wire] - Incyte Corporation today announces five-year data from the Phase 3 COMFORT-I study evaluating the long-term safety and efficacy of Jakafi® in patients with intermediate-2 or high-risk myelofibrosis .
06/06/16 06:20 AMMoffitt collaboration accelerates blood cancer research -
06/02/16 04:53 PMCompany Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Completes the Sale of Its European Operations and ... - Smarter Analyst - Company Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Completes the Sale of Its European Operations and ...Smarter AnalystAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has completed the sale of its European operations to Incyte Corporation and entered into the previously announced license agreement for Incyte to exclusively license Iclusig®(ponatinib) in ...and more »
06/01/16 04:57 PMIncyte (INCY) Europe Granted Exclusive Iclusig Development, Commercialization Rights in EU, Additional Countries ... - StreetInsider.com - Incyte (INCY) Europe Granted Exclusive Iclusig Development, Commercialization Rights in EU, Additional Countries ...StreetInsider.comOn June 1, 2016, an Amended and Restated Buy-in License Agreement was entered into by ARIAD Pharmaceuticals, Inc. (“ARIAD”), ARIAD Pharmaceuticals (Europe) S.a.r.l. (“ARIAD Europe”), and Incyte Corporation (“Incyte”), as guarantor (the “License ...
06/01/16 03:06 PMINCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition -
06/01/16 06:53 AMIncyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance - [at noodls] - www.incyte.com. Follow @Incyte on Twitter at https://twitter.com/Incyte. ... This is an abstract of the original noodl. To continue reading this document, click here for the original version.
05/31/16 04:47 PMBrokerages gives Consensus Recommendation of “Buy” to Incyte Co. (NASDAQ:INCY) - Let Me Know About This - iStreetWireBrokerages gives Consensus Recommendation of “Buy” to Incyte Co. (NASDAQ:INCY)Let Me Know About ThisIncyte logo Incyte Co. (NASDAQ:INCY) has been assigned a consensus rating of “Buy” from the twenty-one research firms that are currently covering the company. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ...Sectoral Asset Management Inc buys $84.5 Million stake in Incyte Corporation (INCY)Market Digestall 5 news articles »
05/31/16 03:35 PMIncyte Announces the Launch of the Incyte Charitable Giving Foundation - [Business Wire] - Incyte Corporation , a biopharmaceutical company, today announced the launch of the Incyte Charitable Giving Foundation, which will provide charitable donations to publicly-funded 501 tax-exempt nonprofit organizations serving the needs of communities in Delaware.
05/31/16 03:19 PMShire’s Shareholders Approve Baxalta Merger: What’s Next? -
05/30/16 08:26 AM2 Biotech Stocks Under $5 With Jaw-Dropping Growth Potential - Motley Fool - Motley Fool2 Biotech Stocks Under $5 With Jaw-Dropping Growth PotentialMotley FoolOn this front, the biotech has launched an early stage trial for AGEN1884, a CTLA-4 antagonist antibody, in solid tumors, and is reportedly close to initiating a second trial via its partnership with Incyte for the GITR agonist antibody INCAGN1876 ...and more »
About Incyte

Incyte logoIncyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company's pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company's second oral JAK1 and JAK2 inhibitor is baricitinib.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: INCY
  • CUSIP: 45337C10
Key Metrics:
  • Previous Close: $78.74
  • 50 Day Moving Average: $79.321
  • 200 Day Moving Average: $79.446
  • P/E Ratio: 317.480
  • P/E Growth: 49.730
  • Market Cap: $14.77B
  • Current Quarter EPS Consensus Estimate: $0.040 EPS
Additional Links:
Incyte (NASDAQ:INCY) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha